The present and future disease burden of hepatitis C virus infections with today's treatment paradigm – volume 3

LAUR Repository

Show simple item record

dc.contributor.author Mokhbat, J. E.
dc.contributor.author Sibley, A.
dc.contributor.author Han, K. H.
dc.contributor.author Abourached, A.
dc.contributor.author Lesmana, L. A.
dc.contributor.author Makara, M.
dc.contributor.author Jafri, W.
dc.contributor.author Salupere, R.
dc.contributor.author Assiri, A. M
dc.date.accessioned 2017-02-10T13:54:06Z
dc.date.available 2017-02-10T13:54:06Z
dc.date.copyright 2015 en_US
dc.date.issued 2017-02-10
dc.identifier.issn 1352-0504 en_US
dc.identifier.uri http://hdl.handle.net/10725/5211
dc.description.abstract The total number, morbidity and mortality attributed to viraemic hepatitis C virus (HCV) infections change over time making it difficult to compare reported estimates from different years. Models were developed for 15 countries to quantify and characterize the viraemic population and forecast the changes in the infected population and the corresponding disease burden from 2014 to 2030. With the exception of Iceland, Iran, Latvia and Pakistan, the total number of viraemic HCV infections is expected to decline from 2014 to 2030, but the associated morbidity and mortality are expected to increase in all countries except for Japan and South Korea. In the latter two countries, mortality due to an ageing population will drive down prevalence, morbidity and mortality. On the other hand, both countries have already experienced a rapid increase in HCV-related mortality and morbidity. HCV-related morbidity and mortality are projected to increase between 2014 and 2030 in all other countries as result of an ageing HCV-infected population. Thus, although the total number of HCV countries is expected to decline in most countries studied, the associated disease burden is expected to increase. The current treatment paradigm is inadequate if large reductions in HCV-related morbidity and mortality are to be achieved. en_US
dc.language.iso en en_US
dc.title The present and future disease burden of hepatitis C virus infections with today's treatment paradigm – volume 3 en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 200902719 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Journal of Viral Hepatitis en_US
dc.journal.volume 22 en_US
dc.journal.issue S4 en_US
dc.article.pages 21-41
dc.identifier.doi http://dx.doi.org/10.1111/jvh.12476 en_US
dc.identifier.ctation Sibley, A., Han, K. H., Abourached, A., Lesmana, L. A., Makara, M., Jafri, W., ... & Abbas, Z. (2015). The present and future disease burden of hepatitis C virus infections with today's treatment paradigm–volume 3. Journal of viral hepatitis, 22(S4), 21-41. en_US
dc.author.email jacques.mokhbat@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url http://onlinelibrary.wiley.com/doi/10.1111/jvh.12476/full en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account